These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9364513)

  • 1. Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.
    Boireau A; Bordier F; Dubédat P; Pény C; Impérato A
    Neurosci Lett; 1997 Oct; 234(2-3):123-6. PubMed ID: 9364513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice.
    D'Astous M; Morissette M; Tanguay B; Callier S; Di Paolo T
    Synapse; 2003 Jan; 47(1):10-4. PubMed ID: 12422368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged alterations in canine striatal dopamine metabolism following subtoxic doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 4'-amino-MPTP are linked to the persistence of pyridinium metabolites.
    Johannessen JN; Sobotka TJ; Weise VK; Markey SP
    J Neurochem; 1991 Sep; 57(3):981-90. PubMed ID: 1677682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selenium partially reverses the depletion of striatal dopamine and its metabolites in MPTP-treated C57BL mice.
    Khan HA
    Neurochem Int; 2010 Nov; 57(5):489-91. PubMed ID: 20619308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased striatal dopamine turnover following acute administration of rotenone to mice.
    Thiffault C; Langston JW; Di Monte DA
    Brain Res; 2000 Dec; 885(2):283-8. PubMed ID: 11102582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
    Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase of striatal dopamine turnover by stress in MPTP-treated mice.
    Urakami K; Masaki N; Shimoda K; Nishikawa S; Takahashi K
    Clin Neuropharmacol; 1988 Aug; 11(4):360-8. PubMed ID: 3264755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
    Muthian G; Mackey V; King J; Charlton CG
    Neuroscience; 2010 Sep; 169(3):1085-93. PubMed ID: 20540993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
    Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
    Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
    Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
    Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice.
    Plangár I; Zádori D; Szalárdy L; Vécsei L; Klivényi P
    Ideggyogy Sz; 2013 Nov; 66(11-12):407-14. PubMed ID: 24555241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effect of riluzole on MPTP-induced depletion of dopamine and its metabolite content in mice.
    Araki T; Kumagai T; Matsubara M; Ido T; Imai Y; Itoyama Y
    Metab Brain Dis; 2000 Sep; 15(3):193-201. PubMed ID: 11206588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
    Rai SN; Yadav SK; Singh D; Singh SP
    J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of chinonin in MPTP-induced C57BL/6 mouse model of Parkinson's disease.
    Feng G; Zhang Z; Bao Q; Zhang Z; Zhou L; Jiang J; Li S
    Biol Pharm Bull; 2014; 37(8):1301-7. PubMed ID: 24871044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
    Boireau A; Dubédat P; Bordier F; Peny C; Miquet JM; Durand G; Meunier M; Doble A
    Neuroreport; 1994 Dec; 5(18):2657-60. PubMed ID: 7696626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of selective, reversible inhibitors of monoamine oxidase on the prolonged depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
    Fuller RW; Hemrick-Luecke SK
    Life Sci; 1985 Sep; 37(12):1089-96. PubMed ID: 3875779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent depletion of striatal dopamine in mice by m-hydroxy-MPTP.
    Fuller RW; Hemrick-Luecke SK
    Res Commun Chem Pathol Pharmacol; 1986 Aug; 53(2):167-72. PubMed ID: 3764080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
    Leng A; Mura A; Hengerer B; Feldon J; Ferger B
    Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective effect of riluzole in MPTP-treated mice.
    Araki T; Kumagai T; Tanaka K; Matsubara M; Kato H; Itoyama Y; Imai Y
    Brain Res; 2001 Nov; 918(1-2):176-81. PubMed ID: 11684056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
    Liu LX; Chen WF; Xie JX; Wong MS
    Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.